Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 121 S Orange Ave Ste 1500 ORLANDO FL 32801-3241 |
Tel: | N/A |
Website: | https://nutriband.com |
IR: | See website |
Key People | ||
Serguei Melnik Chairman of the Board, President, Secretary | Gareth Sheridan Chief Executive Officer, Founder, Director | Gerald Goodman Chief Financial Officer, Chief Accounting Officer |
Alan Smith Chief Operating Officer, President of 4P Therapeutics | Patrick Ryan Chief Technical Officer | Jeff Patrick Chief Scientific Officer |
Business Overview |
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. |
Financial Overview |
For the three months ended 30 April 2024, Nutriband Inc revenues decreased 14% to $409K. Net loss increased 87% to $1.9M. Revenues reflect 4P Therapeutics segment decrease from $76K to $0K. Higher net loss reflects Research and development increase from $400K to $975K (expense), Selling, general and administrative expe increase of 29% to $1.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.13 to -$0.21. |